We are comparing the usual dose of Pembrolizumab with a lower dose for patients with non-squamous lung cancer. The goal is to see if the lower dose is as effective in maintaining treatment benefits.
Health conditions and diseases that the clinical trial is designed to study and treat.
Metastatic non-squamous lung cancer is a type of lung cancer that has spread beyond the lungs to other parts of the body. It is often treated with maintenance therapies to help control the disease and improve quality of life.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
